Sanofi SA vs Zillow Group Inc Class C — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Zillow Group Inc Class C trades at $32.3 (market cap $7.26B). The key difference: Sanofi SA is far larger — about 14.2× Zillow Group Inc Class C's market cap, and Sanofi SA pays a 5.65% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| SNY | Z | |
|---|---|---|
Market Cap | $103.41B | $7.26B |
Sector | Health | Media |
52-Week High | $52.34 | $90.35 |
52-Week Low | $41.33 | $29.41 |
Enterprise Value | $123.44B | $7.14B |
Dividend Yield | 5.65% | — |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Zillow Group (Z) trades at $32.36, down 6.45% amid a challenging housing market. The stock shows bearish technical signals with support at $30 and resistance at $34. Fundamentally, revenue growth continues (2025: $2.58B, 2026: $2.8B projected) with improving profitability (net margin turning positive at 1.96% in 2025). Recent Q2 2026 earnings beat expectations with $0.52 EPS versus $0.4459 expected, though the company faces regulatory scrutiny from a recent FTC settlement.
Despite near-term headwinds, Zillow's transition to an integrated transaction platform and strong rental market presence offer long-term growth potential. Key risks include housing market volatility, competitive pressures, and ongoing legal challenges. Analyst consensus price target of $52 suggests significant upside potential from current levels, though technical indicators remain bearish in the short term.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →